Use of new peritoneal dialysis solutions in children

Kidney International

Volumn 73, Issue SUPPL. 108, 2008, Pages

  Canepa, A ^a   Verrina, E ^a   Perfumo, F ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

Amino acids; Bicarbonate lactate; Icodextrin; PD solutions; Pediatric peritoneal dialysis

Indexed keywords

AMINO ACID; BICARBONATE; DIANEAL; ICODEXTRIN; LACTIC ACID; NUTRINEAL; PERITONEAL DIALYSIS FLUID; DIALYSIS FLUID; GLUCAN; GLUCOSE; LACTIC ACID DERIVATIVE;

ARTICLE; BIOCOMPATIBILITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; HUMAN; MALE; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SCHOOL CHILD; CHILD; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; KIDNEY DISEASE; METHODOLOGY; PATHOPHYSIOLOGY; PH; PHYSIOLOGY; PRESCHOOL CHILD; TRANSPORT AT THE CELLULAR LEVEL; ULTRAFILTRATION;

AMINO ACIDS; BICARBONATES; BIOLOGICAL TRANSPORT; CHILD; CHILD, PRESCHOOL; CIRCADIAN RHYTHM; DIALYSIS SOLUTIONS; FEMALE; GLUCANS; GLUCOSE; HUMANS; HYDROGEN-ION CONCENTRATION; KIDNEY DISEASES; LACTATES; MALE; PERITONEAL DIALYSIS; ULTRAFILTRATION;

EID: 44449147202     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002615     Document Type: Article

References (67)

1. Witowski J, Topley N, Jorres A et al. Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 1995; 47: 282-293.
2. Davies SJ, Phillips L, Naish PF et al. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12: 1046-1051.
3. Krediet RT, Lindholm B, Rippe B. Pathophysiology of peritoneal membrane failure. Perit Dial Int 2000; 20(Suppl 4): S22-S42.
4. Yanez-Mo M, Larra-Pezzi E, Selgas R et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348: 403-413.
5. Topley N, Kaur D, Petersen MM et al. In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function. J Am Soc Nephrol 1996; 7: 218-224.
6. Williams JD, Craig KJ, Topley N et al. Peritoneal dialysis: changes to the structure of the peritoneal membrane and potential for biocompatible solutions. Kidney Int 2003; 63(Suppl 84): S158-S161.
7. Ha H, Cha MK, Choi HN et al. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int 2002; 22: 171-177.
8. Witowski J, Jörres A, Ksiazek K et al. Glucose degradation products in peritoneal dialysis fluids: do they harm? Kidney Int 2003; 63(Suppl 84): S148-S151.
9. Williams JD, Topley N, Craig KJ et al. The Euro-Balance trial: the effect of new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418.
10. Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295: 1681-1687.
11. Delarue J, Maingourd C, Couet C et al. Effects of oral glucose on intermediary metabolism in continuous ambulatory peritoneal dialysis patients versus healthy patients. Perit Dial Int 1998; 18: 505-511.
12. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA Study. J Am Soc Nephrol 2001; 12: 2158-2162.
13. Chung SH, Beimbürger O, Stenvinkel P et al. Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol Dial Transplant 2003; 18: 590-597.
14. Cooker LA, Holmes CJ, Hoff CM. Biocompatibility of icodextrin. Kidney Int 2002; 62(Suppl 81): S34-S45.
15. Holmes CJ, Shockley TR. Strategies to reduce glucose exposure in peritoneal dialysis patients. Perit Dial Int 2000; 20(Suppl 2): S37-S41.
16. Lerner GR, Warady BA, Sullivan EK et al. Chronic dialysis in children and adolescents. The 1996 annual report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1999; 13: 404-417.
17. Verrina E, Edefonti A, Gianoglio B et al. A multicenter experience on patients and technique survival in children on chronic dialysis. Pediatr Nephrol 2004; 19: 82-90.
18. Haas S, Schmitt CP, Arbeiter K et al. Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. J Am Soc Nephrol 2003; 14: 2632-2638.
19. 3 solution with low sodium concentration over standard lactate solutions for acute peritoneal dialysis. Adv Perit Dial 1997; 13: 179-182.
20. Canepa A, Verrina E, Trivelli A et al. Comparison of peritoneal amino acid (aa) losses in children on automatized peritoneal dialysis (apd) using lactate or bicarbonate/lactate-based solutions. Pediatr Nephrol 2000; 14(Supp 1): C94.
21. Fischbach M, Terzic J, Chauvé S et al. Effect of peritoneal dialysis fluid composition on peritoneal area available for exchange in children. Nephrol Dial Transplant 2004; 19: 925-932.
22. Schmitt CP, Haraldsson B, Doetschmann R et al. Effects of pH-neutral, bicarbonate-buffered dialysis fluid on peritoneal transport kinetics in children. Kidney Int 2002; 61: 1527-1536.
23. Gotloib L, Wajsbrot V, Shostak A et al. Population analysis of mesothelium in situ and in vivo exposed to bicarbonate-buffered peritoneal dialysis fluid. Nephron 1996; 73: 219-227.
24. Topley N, Kaur D, Petersen MM et al. Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: influence on mesothelial cell and neutrophil function. Kidney Int 1996; 49: 1447-1456.
25. Jones S, Holmes CJ, Mackenzie RK et al. Continuous dialysis with bicarbonate/lactate-buffered peritoneal dialysis fluids results in a long-term improvement in ex vivo peritoneal macrophage function. J Am Soc Nephrol 2002; 13(Suppl 1): S97-S103.
26. Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution - clinical benefits. The Bicarbonate/Lactate Study Group. Perit Dial Int 2000; 20: 516-523.
27. Liberek T, Topley N, Jörres A et al. Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron 1993; 65: 260-265.
28. Feriani M, Ronco C, La Greca G. Acid-base balance with different CAPD solutions. Perit Dial Int 1996; 16(Suppl 1): S126-S129.
29. Rippe B. A three-pore model of peritoneal transport. Perit Dial Int 1993; 13(Suppl 2): S35-S38.
30. Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 1994; 46: 496-503.
31. Mistry CD, Gokal R. The use of glucose polymer (icodextrin) in peritoneal dialysis: an overview. Perit Dial Int 1994; 14(Suppl 3): S158-S161.
32. Posthuma N, ter Wee PM, Verbrugh HA et al. Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrol Dial Transplant 1997; 12: 550-553.
33. Ho-dac-Pannekeet MM, Schouten N, Langenduck MJ et al. Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int 1996; 50: 979-986.
34. Verrina E, Perfumo F, Gusmano R. Automated peritoneal dialysis prescription and results in children. Contrib Nephrol 1999; 129: 123-133.
35. de Boer AW, Schroeder CH, van Vliet R et al. Clinical experience with icodextrin in children: ultrafiltration profiles and metabolism. Pediatr Nephrol 2000; 15: 21-24.
36. Posthuma N, ter Wee PM, Donker AJ et al. Serum disaccharides and osmolality in CCPD patients using icodextrin or glucose as daytime dwell. Perit Dial Int 1997; 17: 602-607.
37. van Hoeck KJ, Rusthoven E, Vermeylen L et al. Nutritional effects of increasing dialysis dose by adding an icodextrin daytime dwell to Nocturnal Intermittent Peritoneal Dialysis (NIPD) in children. Nephrol Dial Transplant 2003; 18: 1383-1387.
38. Rusthoven E, Krediet RT, Willems HL et al. Peritoneal transport characteristics with glucose polymer-based dialysis fluid in children. J Am Soc Nephrol 2004; 15: 2940-2947.
39. Rusthoven E, van der Vlugt ME, van Lingen-van Bueren LJ et al. Evaluation of intraperitoneal pressure and the effect of different osmotic agents on intraperitoneal pressure in children. Perit Dial Int 2005; 25: 352-356.
40. Stelin G, Rippe B. A phenomenological interpretation of the variation of dialysate volume with dwell time in CAPD. Kidney Int 1990; 38: 465-472.
41. Haycock GB, Chir B, Schwarta GJ et al. Geometric method for measuring body surface area. A height-weight formula validated in infants, children, and adults. J Pediatr 1978; 93: 62-66.
42. Wang R, Moberly JB, Shockley TR et al. A rapid assay for icodextrin determination in plasma and dialysate. Adv Perit Dial 2002; 18: 91-95.
43. Rusthoven E, Krediet RT, Willems HL et al. Sodium sieving in children. Perit Dial Int 2005; 25(Suppl 3): S141-S142.
44. Ota K, Akiba T, Nakao T et al. Peritoneal ultrafiltration and serum icodextrin concentration during dialysis with 7.5% icodextrin solution in Japanese patients. Perit Dial Int 2003; 23: 356-361.
45. Schaefer F, Klaus G, Muller-Wiefel DE et al. Current practice of peritoneal dialysis in children: results of a longitudinal survey. Mid European Pediatric Peritoneal Dialysis Study Group (MEPPS). Perit Dial Int 1999; 19(Suppl 2): S445-S449.
46. Salusky IB, Fine RN, Nelson P et al. Nutritional status of children undergoing continuous ambulatory peritoneal dialysis. Am J Clin Nutr 1983; 38: 599-611.
47. Canepa A, Perfumo F, Carrea A et al. Nutritional status in children receiving chronic peritoneal dialysis. Perit Dial Int 1996; 16(Suppl 1): S526-S531.
48. Canepa A, Divino Filho JC, Forsberg AM et al. Children on continuous ambulatorial peritoneal dialysis: muscle and plasma proteins, amino acids and nutritional status. Clin Nephrol 1996; 46: 125-131.
49. Broyer M, Niaudet P, Champion G et al. Nutritional and metabolic studies in children on continuous ambulatory peritoneal dialysis. Kidney Int 1983; 15(Suppl): S106-S110.
50. Young GA, Dibble JB, Hobson SM et al. The use of an amino-acid-based CAPD fluid over 12 weeks. Nephrol Dial Transplant 1989; 4: 285-292.
51. Goodship TH, Lloyd S, McKenzie PW et al. Short-term studies on the use of amino acids as an osmotic agent in continuous ambulatory peritoneal dialysis. Clin Sci (Lond) 1987; 73: 471-478.
52. Hanning RM, Balfe JW, Zlotkin SH. Effectiveness and nutritional consequences of amino acid-based vs glucose-based dialysis solutions in infants and children receiving CAPD. Am J Clin Nutr 1987; 46: 22-30.
53. Lindholm B, Werynski A, Bergstrom J. Peritoneal dialysis with amino acid solutions: fluid and solute transport kinetics. Artif Organs 1988; 12: 2-10.
54. Bruno M, Bagnis C, Marangella M et al. CAPD with an amino acid dialysis solution: a long-term, cross-over study. Kidney Int 1989; 35: 1189-1194.
55. Renzo S, Beatrice D, Giuseppe I. CAPD in diabetics: use of aminoacids. Adv Perit Dial 1990; 6: 53-55.
56. Kopple JD, Bernard D, Messana J et al. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 1995; 47: 1148-1157.
57. Faller B, Aparicio M, Faict D et al. Clinical evaluation of an optimized 1.1% amino-acid solution for peritoneal dialysis. Nephrol Dial Transplant 1995; 10: 1432-1437.
58. Haming RM, Balfe JW, Zlottin SH. Effectiveness and nutritional consequences of aminoacid-based vs glucose-based dialysis solutions in infants and children receiving CAPD. Am J Clin Nutr 1987; 46: 22-30.
59. Qamar IU, Levin L, Balfe JW et al. Effects of 3-month amino acid dialysis compared to dextrose dialysis in children on continuous ambulatory peritoneal dialysis. Perit Dial Int 1994; 14: 34-41.
60. Canepa A, Perfumo F, Carrea A et al. Long-term effect of amino-acid dialysis solution in children on continuous ambulatory peritoneal dialysis. Pediatr Nephrol 1991; 5: 215-219.
61. Qamar IU, Secker D, Levin L et al. Effects of amino acid dialysis compared to dextrose dialysis in children on continuous cycling peritoneal dialysis. Perit Dial Int 1999; 19: 237-247.
62. Honda M, Kamiyama Y, Hasegawa O et al. Effect of short-term essential amino acid-containing dialysate in young children on CAPD. Perit Dial Int 1991; 11: 76-80.
63. Brem AS, Maaz D, Shemin DG et al. Use of amino acid peritoneal dialysate for one year in a child on CCPD. Perit Dial Int 1996; 16: 634-636.
64. Canepa A, Carrea A, Menoni S et al. Acute effects of simultaneous intraperitoneal infusion of glucose and amino acids. Kidney Int 2001; 59: 1967-1973.
65. Garibotto G, Sofia A, Canepa A et al. Acute effects of peritoneal dialysis with dialysates containing dextrose or dextrose and amino acids on muscle protein turnover in patients with chronic renal failure. J Am Soc Nephrol 2001; 12: 557-567.
66. Tjiong HL, van den Berg JW, Wattimena JL et al. Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. J Am Soc Nephrol 2005; 16: 1486-1493.
67. Canepa A, Verrina E, Perfumo F et al. Value of intraperitoneal amino acids in children treated with chronic peritoneal dialysis. Perit Dial Int 1999; 19(Suppl 2): S435-S440.